Zyla life sciences (EGLT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net (loss) income

-54,396

-46,640

0

0

0

-

-

-

-

-69,359

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-59,760

-

-59,635

-52,449

-47,019

-43,214

0

0

0

Adjustment to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization

14,804

13,576

0

0

0

-

-

-

-

5,062

5,189

4,981

4,725

4,118

3,494

3,237

3,205

3,014

2,442

1,812

1,104

641

0

0

0

Change in fair value of warrant and derivative liability

-

-

-

-

-

-

0

-

-

2,546

1,515

3

46

644

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

2,743

2,237

0

0

0

-

-

-

-

5,918

6,702

6,817

6,801

6,323

6,161

5,647

5,400

5,199

4,729

5,431

7,949

8,518

0

0

0

Non-cash interest and amortization of debt discount

5,627

6,111

0

0

0

-

-

-

-

5,070

6,481

6,373

5,219

5,911

0

0

0

-

-

-

-

-

-

-

-

Noncash interest and amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Accretion of discount on marketable securities

-

-3

0

0

0

-

-

-

-

-24

103

212

330

607

0

0

0

-

-

-

-

-

-

-

-

Change in right of use assets

-734

-818

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

8,783

4,983

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,061

-1,502

-1,144

-929

-718

0

0

0

-

-

-

0

Changes in assets and liabilities:
Related party receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-57

-99

-534

-412

-563

22

311

395

744

0

0

0

Accounts receivable

-8,881

21,556

0

0

0

-

-

-

-

3,012

1,717

4,287

4,581

813

0

0

0

-

-

-

-

-

-

-

-

Inventory

-12,995

-24,789

0

0

0

-

-

-

-

1,525

348

207

-626

-137

-2,065

-2,145

-1,311

-1,571

0

0

0

-

-

-

-

Prepaid expenses

188

159

0

0

0

-

-

-

-

132

-469

225

-39

1,243

-82

493

529

631

1,186

199

503

540

0

0

0

Other receivables

880

685

0

0

0

-

-

-

-

-219

-186

80

-1,110

-28

0

0

0

-

-

-

0

-

-

-

-

Deposits and other assets

223

1,467

0

0

0

-

-

-

-

375

1,112

120

-976

-1,481

-1,414

1,707

1,613

2,050

0

0

0

-

-

-

-

Accounts payable

11,533

4,416

0

0

0

-

-

-

-

7,597

-85

-2,109

2,043

-2,945

2,244

1,571

1,682

1,147

2,210

1,271

1,798

3,268

0

0

0

Accrued expenses

-3,603

3,582

0

0

0

-

-

-

-

-2,132

3,969

12,240

7,300

10,553

8,832

3,521

3,301

5,123

2,305

4,092

3,917

1,412

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

3,475

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,153

-25,150

-24,586

-14,814

1,485

21,268

22,829

14,100

-557

0

0

0

Other current liabilities

-13

-45

0

0

0

-

-

-

-

-

-497

-379

-242

-187

431

265

189

116

1

59

-10

32

0

0

0

Other liabilities

570

682

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-

-

-179

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

10,762

-10,964

0

0

0

-

-

-

-

-65,164

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-57,862

-

-26,850

-16,299

-19,830

-25,074

0

0

0

Payments for purchase of property and equipment

37

40

0

0

0

-

-

-

-

88

-1,747

1,092

3,691

7,237

11,117

8,335

6,194

2,747

3,166

3,081

2,967

2,889

0

0

0

Deposits for purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of investments

-

-

-

-

-

-

-

-

-

101,338

107,414

74,396

88,777

59,545

0

0

0

-

-

-

-

-

-

-

-

Sales of investments

-

2,497

0

0

0

-

-

-

-

-

-

-

-

14,370

0

0

0

-

-

-

-

-

-

-

-

Maturity of investments

-

2,500

0

0

0

-

-

-

-

71,647

79,572

72,772

87,516

101,277

0

0

0

-

-

-

-

-

-

-

-

Purchase of SPRIX Nasal Spray

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,128

0

0

0

-

-

-

-

License of OXAYDO

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,672

0

0

0

-

-

-

-

Net cash (used in) provided by investing activities

-24

4,970

0

0

0

-

-

-

-

-17,584

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

32,888

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from IPO, net of costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payments of contingent consideration

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on borrowings

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of tax withholdings on restricted stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from credit agreement

-

3,770

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from debt and royalty rights

-

-

-

-

-

-

-

-

-

38,304

0

0

0

-

-

-

-

71,397

0

0

0

-

-

-

-

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-100,486

-

-108,547

-66,248

-17,010

-3,743

0

0

0

Royalty payments in connection with the 13% Notes

-

-

-

-

-

-

-

-

-

307

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-6,676

914

0

0

0

-

-

-

-

69,353

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign currency translation on cash and cash equivalents

93

-2

0

0

0

-

-

-

-

530

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) cash, cash equivalents and restricted cash

4,155

-5,082

0

0

0

-

-

-

-

-12,865

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

152,361

71,578

14,521

66,982

0

0

0

Effect of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

948

-

469

-624

-1,244

-1,127

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,310

-30,536

-22,645

-19,720

-6,073

0

0

0

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37,038

0

0

0

Supplemental disclosures of cash flow information:
Conversion of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,957

0

0

0

Issuance of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Cash interest payments

0

-

-

-

-

-

-

-

-

12,817

11,810

7,762

6,454

4,712

4,479

5,309

5,299

3,461

0

0

0

-

-

-

-

Non-cash financing activities:
Conversion of related party convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24,713

0

0

0

Liability for contractual payment associated with OXAYDO license

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Predecessor
Net (loss) income

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and derivative liability

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest and amortization of debt discount

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on marketable securities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits and other assets

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by operating activities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments for purchase of property and equipment

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturity of investments

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty payments in connection with the 13% Notes

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash interest payments

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification to additional paid-in capital of derivative liability

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-